An independent evaluation of the pilot phase of the Medicines Transparency Alliance (MeTA) programme was carried out between December 2009 and February 2010. The report assessment shows that the MeTA approach is beginning to show signs of real impact. Multi-stakeholder groups are engaged in constructive dialogue, critical information on the pharmaceutical sector is being collected, public-awareness campaigns launched and policy reforms initiated. The evaluation also provides some valuable guidance on how the MeTA model could be strengthened. The report highlights how DFID, the World Health Organisation and the World Bank could align more closely in working with pilot countries. We now know how better to use the different tools available to analyse the pharmaceutical sector, how to sequence activities in the MeTA process more effectively and how to allow sufficient time in the planning process for establishing the multi-stakeholder groups. It has tested new approaches and innovative new tools while generating valuable lessons on how increased transparency and accountability can improve the access of the poor to essential medicines. MeTA has fulfilled its mandate as a pilot programme.
Evaluation of the Medicines Transparency Alliance Phase 1 2008-2010Authors: Health Partners International
Document Type: Reports
Publication Date: 2010